Investment Rating - The report initiates coverage with a "Buy" rating for the company [1] Core Views - The company is the largest OTC manufacturer in China, with a strong brand presence and a projected revenue compound annual growth rate (CAGR) of 7.5% from 2019 to 2024 [6][26] - The pharmaceutical manufacturing segment ranks second in the industry, while the pharmaceutical distribution segment ranks third [6][65] - The company has a robust pipeline of acquisitions to expand its business scope, particularly in traditional Chinese medicine and healthcare products [7][38] Summary by Sections Company Overview - China Resources Pharmaceutical Group Limited is a leading integrated pharmaceutical company, covering manufacturing and distribution of pharmaceuticals, healthcare products, and medical devices [20] - The company has a significant market presence, with a market capitalization of HKD 285.23 billion and a closing price of HKD 4.54 as of January 16, 2026 [1] Financial Performance - The company’s revenue for the first half of 2025 reached CNY 1,319 billion, with a year-on-year growth of 3% [26] - The distribution business accounted for approximately 80% of total revenue, with distribution revenue of CNY 1,045 billion, growing by 2% [26] - The pharmaceutical business generated CNY 218 billion in revenue, increasing its share from 15% in 2019 to 17% in the first half of 2025 [26] Pharmaceutical Manufacturing - The company produces 944 products, including traditional Chinese medicine, chemical drugs, biological products, and medical devices, covering a wide range of therapeutic areas [32] - The pharmaceutical business is expected to grow at a CAGR of 10.4% from 2022 to 2024 [36] Pharmaceutical Distribution - The company’s distribution revenue for the first half of 2025 was CNY 1,100 billion, ranking third in the industry, behind China National Pharmaceutical Group and Shanghai Pharmaceuticals [8][65] - The distribution model is evolving from traditional distribution to a dual approach of distribution and deep marketing [8] Profit Forecast and Valuation - The projected net profit attributable to ordinary shareholders for 2025-2027 is CNY 34.9 billion, CNY 37.6 billion, and CNY 40.5 billion, respectively, with growth rates of 4.0%, 7.9%, and 7.7% [9] - The report assigns a price-to-earnings (PE) ratio of 8.7x for 2026, suggesting a market value of HKD 353 billion, indicating a 24% upside potential from the current market value [8] Key Assumptions - The pharmaceutical business is expected to grow at rates of 4.1%, 6.0%, and 6.5% from 2025 to 2027 [12] - The distribution business is projected to grow at rates of 2.6%, 5.0%, and 5.3% during the same period [12] - The retail business is anticipated to grow at rates of 11.8%, 12.0%, and 12.0% from 2025 to 2027 [12]

Core Viewpoint - The company has publicly disclosed the list of candidates for the first phase of the restricted stock incentive plan, confirming that all candidates meet the necessary qualifications and legal requirements [1][2]. Group 1: Public Disclosure - The company conducted an internal public announcement of the list of candidates for the reserved grant of restricted stock from December 30, 2025, to January 9, 2026, involving 31 individuals [1]. - During the public announcement period, no objections were raised by any organization or individual regarding the list of candidates [1]. Group 2: Verification Opinions - The company's Board of Directors' Compensation and Assessment Committee verified that all candidates meet the qualifications stipulated by relevant laws and regulations, including the Company Law and Securities Law, as well as the company's internal regulations [1][2]. - The candidates do not include independent directors, supervisors, or shareholders holding more than 5% of the company's shares, ensuring compliance with the regulations [1].

Core Viewpoint - The company has publicly disclosed the list of reserved grant incentive objects for the first phase of its restricted stock incentive plan, confirming that all candidates meet the necessary qualifications and legal requirements [1][2][3]. Disclosure Situation - The company conducted an internal public announcement of the reserved grant incentive object list from December 30, 2025, to January 9, 2026, involving 31 individuals [1]. - During the public announcement period, no organization or individual raised any objections to the list of incentive objects [1]. Verification Opinions - The board's remuneration and assessment committee confirmed that all reserved grant incentive objects meet the qualifications stipulated by relevant laws and regulations, including the Company Law and Securities Law, and do not fall under any disqualifying conditions [2][3]. - The basic information regarding the reserved grant incentive objects is accurate, with no instances of falsehood or significant misunderstanding [3].

证券代码：000423 证券简称：东阿阿胶 公告编号：2026-03 东阿阿胶股份有限公司 董事会薪酬与考核委员会关于第一期限制性股票激励计划 预留授予激励对象名单公示情况的说明及核查意见 本公司及董事会薪酬与考核委员会全体成员保证信息披露的内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 根据《中央企业控股上市公司实施股权激励工作指引》（以下简称《工作指 引》）、《上市公司股权激励管理办法》（以下简称《管理办法》）及东阿阿胶 股份有限公司（以下简称"公司"）《第一期限制性股票激励计划（草案二次修 订稿）》（以下简称《激励计划》）等有关规定，公司对第一期限制性股票激励 计划拟授予预留限制性股票的激励对象名单，在公司内部进行了公示。 公司董事会薪酬与考核委员会结合公示情况，对激励对象名单进行了核查， 相关公示情况及核查意见如下： 一、公示情况 公司于 2025 年 12 月 30 日至 2026 年 1 月 9 日，在公司内部对预留授予激励 对象名单进行了公示，人数为 31 人。 公司董事会薪酬与考核委员会根据《工作指引》《管理办法》《激励计划》 和《公司章程》等规定,结合对激励对象名单的审核结果及 ...

Group 1 - In December 2025, the enthusiasm for stock buybacks in the A-share market significantly increased, with both the number of companies announcing buyback plans and the total amount seeing substantial growth [1] - A total of 35 companies announced new buyback plans in December, representing an increase of nearly 60% compared to 22 companies in November [1] - The total proposed buyback amount for these 35 companies reached approximately 10.548 billion yuan, a 54.89% increase from 6.81 billion yuan in November [1] - Among these companies, 24 planned to buy back over 100 million yuan, accounting for 68.57% of the total [1] Group 2 - State-owned enterprises and industry leaders showed prominent performance in the buyback announcements, with notable companies like China Metallurgical Group and Dong'e Ejiao participating [1] - The companies with the highest proposed buyback amounts included China Metallurgical Group (2.5 billion yuan), Luxshare Precision (2 billion yuan), ZTE Corporation (1.2 billion yuan), and others, highlighting the financial strength and market responsibility of leading enterprises [1]

Group 1 - The company Dong-E E-Jiao (000423) will disclose its 2025 annual report on March 20, 2026 [1]

Group 1 - The core point of the article is that Dong'e Ejiao (000423) has responded to investor inquiries, indicating that the total number of shareholders is expected to reach 87,763 by December 31, 2025 [1]

Group 1: Share Buyback Announcement - The company has approved a share buyback plan using its own or raised funds through a concentrated bidding method, with a maximum buyback price of RMB 72.08 per share [2][3] - The estimated minimum number of shares to be repurchased is 138,730 shares, while the maximum is 2,774,700 shares, with the actual number to be determined by the completion of the buyback period [2] - As of December 31, 2025, the company has repurchased a total of 1,628,600 shares, accounting for 0.25% of the total share capital, with a total transaction amount of approximately RMB 79.99 million [2] Group 2: Investment in Healthcare Fund - The company has committed RMB 60 million to participate in the establishment of the China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund, with a total fund size of RMB 1 billion [8][9] - The fund has completed its registration with the Asset Management Association of China and has received the private fund registration certificate as of December 30, 2025 [10] - The fund aims to invest in the health and wellness sector, leveraging the expertise and resources of the fund manager [8]

格隆汇1月5日丨东阿阿胶(000423.SZ)公布，截至2025年12月31日，公司通过股票回购专用证券账户， 以集中竞价交易方式累计回购股份数量为1,628,600股，约占公司总股本的0.25%，最高成交价为49.24 元/股，最低成交价为48.80元/股，成交总金额为79,992,687.96元人民币（不含交易费用）。本次回购符 合既定的回购股份方案以及相关法律法规的要求。 ...

Core Viewpoint - Dong'e Ejiao (000423.SZ) has announced the completion of the registration of the Huaren (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) with the Asset Management Association of China, in compliance with relevant laws and regulations [1] Group 1 - The fund has obtained the Private Investment Fund Registration Certificate [1] - The first phase of capital contribution has been completed [1]